Global EconomyLivemint•1 min read•11/18/2026 (1h ago)

After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally?

After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally?
60-Word AI Digest

Sellas shares climbed after its Phase 3 trial of GPS showed a significant survival benefit for patients with acute myeloid leukemia and no new safety concerns. The company plans to discuss an accelerated filing strategy with the FDA and aims to submit an application in 2027.

Key Takeaways

  • Sellas shares climbed after its Phase 3 trial of GPS showed a significant survival benefit for patients with acute myeloid leukemia and no new safety concerns.
  • The company plans to discuss an accelerated filing strategy with the FDA and aims to submit an application in 2027.
  • Full details and original dispatch available below.

Sellas shares climbed after its Phase 3 trial of GPS showed a significant survival benefit for patients with acute myeloid leukemia and no new safety concerns. The company plans to discuss an accelerated filing strategy with the FDA and aims to submit an application in 2027.

Original Publisher Attribution

This summary was curated from Livemint.

Read Original on Livemint
After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally? — Loop60